Figures computed from official regulatory filings — .
Analysttarget 6.89 USD (+173%) · consensus 4/5 · 5 buy · 5 hold · 0 sell
Ownershipinsiders 21.84% · institutions 50.88% · short 6.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Zentalis Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
17 buys447 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Bruns Ingmar | Award | $21.2K | SEC |
| WALTERS GROUP | Buy | $15.2M | conv 57First in 12mo | SEC |
| Skvarka Jan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Myers Scott Dunsethtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kariuki Enoch | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Johnson David Michaeltrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Walker Luke Nathaniel | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Campbell Shannon | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EASTLAND JULIA MARIE | Sell | $19.1K | SEC |
| EASTLAND JULIA MARIE | Sell | $2.1K | SEC |
| Bruns Ingmar | Sell | $800.7 | SEC |
| Bruns Ingmar | Sell | $7.2K | SEC |
| Vultaggio Vincent | Sell | $72.8K | Unusual size | SEC |
| Vultaggio Vincent | Sell | $8.1K | SEC |
| Vultaggio Vincent | Sell | $16.7K | SEC |
| Vultaggio Vincent | Sell | $6.5K | SEC |
| Vultaggio Vincent | Sell | $1.4K | Unusual size | SEC |
| Vultaggio Vincent | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EASTLAND JULIA MARIE | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bucher James B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bruns Ingmar | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WALTERS WILLIAM THURMAN | Buy | $7.8M | conv 74First in 12mo | SEC |
| GOEL DAVID E. | Sell | $10M | SEC |
| Bucher James B | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Johnson David Michaeltrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |